Navigation Links
Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
Date:10/18/2009

LA JOLLA, Calif., Oct. 18 /PRNewswire/ -- Fate Therapeutics, Inc. announced today the generation of human induced pluripotent stem cells (iPSCs) using a combination of small molecules that significantly improves the speed and efficiency of reprogramming. The discoveries, which were made by Sheng Ding, Ph.D., under a research collaboration between Fate Therapeutics and The Scripps Research Institute (TSRI), represent a more than 200 fold improvement in reprogramming efficiency and reduce the reprogramming period to two weeks as compared to methods using only the four reprogramming factors (Oct 3/4, Sox2, Klf4 and c-Myc). This latest advancement has broad implications for the creation of "pharmaceutical grade" iPSCs, reprogrammed cells that can be produced without genetic modification at commercial scale quantity, quality and consistency and continues to bolster the leadership position of Fate Therapeutics in industrialized iPSC technology. The Company is developing minimally invasive techniques for reprogramming and differentiation and has exclusively in-licensed from TSRI and the Whitehead Institute for Biomedical Research an intellectual property portfolio related to iPSC technology dating back to November 2003.

"While recent studies have reported improved methods of reprogramming, those techniques have relied on further genetic manipulation or have not otherwise addressed a fundamental reprogramming challenge - that iPSC generation is still a very slow and inefficient process and results in a heterogeneous population of cells," said Paul Grayson, president and CEO of Fate Therapeutics. "Once again, Dr. Ding and his team are the first group to clear yet another major hurdle required for the widespread commercial use of iPSCs for drug discovery and patient therapies."

The findings of Dr. Ding and his colleagues are published today in the Advanced Online edition of the scientific journal Nature Methods. As compared to using the four reprogramming factors of Oct 3/4, Sox2, Klf4 and c-Myc alone, Dr. Ding discovered a combined chemical approach that dramatically improves (> 200 fold) the generation of iPSCs from human fibroblasts within two weeks of retroviral transduction. The iPSC colonies generated by the Ding team using a three compound cocktail could be stably expanded over the long term (20+ passages), closely resembled human embryonic stem cells in terms of morphology and pluripotency marker expression and could be differentiated into derivatives of all the three germ layers both in vitro and in vivo.

"Once we achieved reprogramming with cell penetrating proteins, we targeted certain biological pathways that might improve speed and efficiency so as to enable the commercial scale production of patient-specific iPSCs for medical use," said Dr. Ding, associate professor of TSRI and scientific founder of Fate Therapeutics. "When combined with non-viral, non-DNA based methods for iPSC generation, we believe these discoveries create a powerful platform for safer, more efficient reprogramming of human somatic cells."

Earlier this year, under a research collaboration with Fate Therapeutics and TSRI, Dr. Ding and his team of scientists became the first group to generate iPSCs using non-viral, non-DNA based reprogramming methods. Instead of inserting the reprogramming factors of Oct 3/4, Sox2, Klf4 and c-Myc with DNA-based methods, such as viruses or plasmids, the scientists engineered and used recombinant proteins to reprogram cells without genetic modifications. The scientists found that those reprogrammed embryonic-like cells - dubbed "protein induced pluripotent stem cells" or "piPSCs" - from fibroblasts behave indistinguishably from classic embryonic stem cells in their molecular and functional features, including differentiation into various cell types, such as beating cardiac muscle cells, neurons, and pancreatic cells.

About Fate Therapeutics, Inc.

Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop Stem Cell Modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. Fate's SCM approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases. The Company is currently conducting a Phase 1b clinical trial of FT1050, a small molecule SCM designed to increase hematopoietic stem cell number and function in dual umbilical cord blood transplant recipients with hematologic malignancies. In addition, Fate Therapeutics and Stemgent have formed an alliance - CATALYST - a collaborative program to provide its members with first access to the most advanced iPSC technologies for drug discovery and development. Fate Therapeutics is headquartered in La Jolla, CA. For more information, please visit http://www.fatetherapeutics.com.

SOURCE Fate Therapeutics, Inc.


'/>"/>
SOURCE Fate Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch
2. The Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
3. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
4. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
5. Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease
6. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
7. New Oxygen Biotherapeutics, Inc. Investor Presentation Available on Company Website
8. Reportlinker Adds Stem Cell Therapeutics Markets Report
9. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
10. Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index
11. Volcano Corporation Announces Schedule of Events for the 2009 Transcatheter Cardiovascular Therapeutics (TCT) Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... , ... Proove Biosciences, Inc. , the commercial and research leader in ... . The partnership is designed to advance research in pain genetics in an effort ... With the new agreement, researchers at Proove Biosciences are able to collaborate with Luda ...
(Date:5/4/2016)... ... May 04, 2016 , ... The Children’s Tumor Foundation announced its ... tumors to grow on nerves throughout the body. It affects 1 in 3,000 people ... events held during the month of May, as well as online activities, Neurofibromatosis Awareness ...
(Date:5/4/2016)... ... May 04, 2016 , ... PBI-Gordon Corporation is pleased to ... , Doug began his career at PBI-Gordon in February 1988, after finishing his ... variety of roles, ranging from customer service to national product manager, to helping develop, ...
(Date:5/3/2016)... 2016 The report "Biochips ... Gene Expression) Lab-on-a-chip (IVD & POC, Proteomics), ... Centers), Fabrication Technology (Microarrays, Microfluidics) - Forecast ... is expected to reach USD 17.75 Billion ... 2015, growing at a CAGR of 18.4% ...
Breaking Biology Technology:
(Date:3/15/2016)... , March 15, 2016 Yissum ... , the technology-transfer company of the Hebrew University, announced ... of remote sensing technology of various human biological indicators. ... raising $2.0 million from private investors. ... based on the detection of electromagnetic emissions from sweat ...
(Date:3/10/2016)... 2016 --> ... "Identity and Access Management Market by Component (Provisioning, Directory ... by Organization Size, by Deployment, by Vertical, and by ... The market is estimated to grow from USD 7.20 ... at a Compound Annual Growth Rate (CAGR) of 12.2% ...
(Date:3/8/2016)... , March 8, 2016   Valencell ... technology, today announced it has secured $11M in ... GII Tech, a new venture fund being launched ... additional participation from existing investors TDF Ventures and ... funds to continue its triple-digit growth and accelerate ...
Breaking Biology News(10 mins):